Treatment of hidradenitis suppurativa with adalimumab in the PIONEER I and II randomized controlled trials reduced indices of systemic inflammation, recognized risk factors for cardiovascular disease
Clinical and Experimental Dermatology2024Vol. 50(2), pp. 339–347
Citations Over TimeTop 10% of 2024 papers
Abstract
Treatment of patients with HS with ADA resulted in rapid sustained reduction in systemic inflammation, measured by the biomarkers SII, NLR, PLR and MLR, which correlate with CVD risk. SII, NLR and PLR may predict ADA response, although this may be dependent on their interaction with the number of draining fistulae.
Related Papers
- → Treatment of severe recalcitrant hidradenitis suppurativa with adalimumab(2009)21 cited
- → Hidradenitis suppurativa in Crohn’s disease during adalimumab therapy: a paradox?(2016)16 cited
- Adalimumab treatment for hidradenitis suppurativa associated with Crohn's disease.(2014)
- → Hidradenitis suppurativa successfully treated with adalimumab(2015)
- → 15162 Effectiveness of adalimumab in hidradenitis suppurativa: A real-world study(2020)